Lexapro is a brand name of escitalopram, approved by the FDA in the following formulation(s):
LEXAPRO (escitalopram oxalate - solution; oral)
Manufacturer: FOREST LABS
Approval date: November 27, 2002
Strength(s): EQ 5MG BASE/5ML [RLD]
LEXAPRO (escitalopram oxalate - tablet; oral)
Manufacturer: FOREST LABS
Approval date: August 14, 2002
Strength(s): EQ 10MG BASE, EQ 20MG BASE [RLD], EQ 5MG BASE
Has a generic version of Lexapro been approved?
No. There is currently no therapeutically equivalent version of Lexapro available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lexapro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Crystalline composition containing escitalopram
Patent 6,916,941
Issued: July 12, 2005
Inventor(s): Christensen; Troels Volsgaard & Liljegren; Ken & Elema; Michiel Onne & Andresen; Lene & Mahashabde; Shashank & Assenza; Sebastian P.
Assignee(s): H. Lundbeck A/S
Crystalline particles of escitalopram oxalate with a particle size of at least 40 μm is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
Patent expiration dates:
- August 12, 2022
✓
Drug substance
✓
Drug product
- February 12, 2023
✓
Pediatric exclusivity
✓
Drug substance
✓
Drug product
Crystalline composition containing escitalopram
Patent 7,420,069
Issued: September 2, 2008
Inventor(s): Christensen; Troels Volsgaard & Liljegren; Ken & Elema; Michiel Onne & Andresen; Lene & Mahashabde; Shashank & Assenza; Sebastian P.
Assignee(s): H. Lundbeck A/S
Crystalline particles of escitalopram oxalate with a particle size of at least 40 μm is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
Patent expiration dates:
- August 12, 2022
✓
Drug product
- February 12, 2023
✓
Pediatric exclusivity
Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof
Patent RE34712
Issued: August 30, 1994
Inventor(s): Boegesoe; Klaus P. & Perregaard; Jens K.
Assignee(s): H. Lundbeck A/S
The two enantiomers of the anti-depressant drug of the formula I ##STR1## are disclosed. Methods for resolving intermediates and their .[.steroselective.]. .Iadd.stereoselective .Iaddend.conversion to a corresponding .[.enatiomer.]. .Iadd.enantiomer .Iaddend.of I are also disclosed.
Patent expiration dates:
- September 14, 2011
✓
Drug substance
✓
Drug product
- March 14, 2012
✓
Pediatric exclusivity
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
See also...
- Lexapro Consumer Information (Drugs.com)
- Lexapro Consumer Information (Wolters Kluwer)
- Lexapro Solution Consumer Information (Wolters Kluwer)
- Lexapro Consumer Information (Cerner Multum)
- Lexapro Advanced Consumer Information (Micromedex)
- Lexapro AHFS DI Monographs (ASHP)
- Escitalopram Consumer Information (Wolters Kluwer)
- Escitalopram Solution Consumer Information (Wolters Kluwer)
- Escitalopram Consumer Information (Cerner Multum)
- Escitalopram Advanced Consumer Information (Micromedex)
- Escitalopram Oxalate AHFS DI Monographs (ASHP)
